Results add to data suggesting that SVR can be achieved with the combination of daclatasvir (BMS-790052) and asunaprevir (BMS-650032) in HCV genotype 1b patients Study expanded to include alfa/RBV ineligible or intolerant patients Bristol-Myers Squibb Company (NYSE: BMY) announced results from...